These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 7783415

  • 1. Long-term thromboxane-synthase inhibition prolongs survival in murine lupus nephritis.
    Salvati P, Lamberti E, Ferrario R, Ferrario RG, Scampini G, Pugliese F, Barsotti P, Patrono C.
    Kidney Int; 1995 Apr; 47(4):1168-75. PubMed ID: 7783415
    [Abstract] [Full Text] [Related]

  • 2. Abnormal prostanoid metabolism in lupus nephritis and the effects of a thromboxane A2 synthetase inhibitor, DP-1904.
    Yoshida T, Ichikawa Y, Tojo T, Homma M.
    Lupus; 1996 Apr; 5(2):129-38. PubMed ID: 8743126
    [Abstract] [Full Text] [Related]

  • 3. Effect of selective inhibition of thromboxane synthesis on renal function in diabetic nephropathy.
    Kontessis PS, Jones SL, Barrow SE, Stratton PD, Alessandrini P, De Cosmo S, Ritter JM, Viberti GC.
    J Lab Clin Med; 1993 Mar; 121(3):415-23. PubMed ID: 8445289
    [Abstract] [Full Text] [Related]

  • 4. Improvement of renal function with a selective thromboxane A2 synthetase inhibitor, DP-1904, in lupus nephritis.
    Yoshida T, Kameda H, Ichikawa Y, Tojo T, Homma M.
    J Rheumatol; 1996 Oct; 23(10):1719-24. PubMed ID: 8895147
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The effect of a thromboxane A2 synthase inhibitor on the dyslipoproteinemia of an inbred rat strain with spontaneous age-related nephrotic syndrome.
    Tarugi P, Nicolini S, Albertazzi L, Marchi L, Calandra S, Salvati P.
    Aging (Milano); 1994 Oct; 6(5):381-90. PubMed ID: 7893785
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pharmacological characterization of FCE 27262, a combined thromboxane synthase inhibitor and PGH2/TXA2 receptor antagonist.
    Vaghi F, Colombo M, Pierucci L, Volpi D, Dho L, Ukmar G, Rosa B, Salvati P.
    Drugs Exp Clin Res; 1993 Oct; 19(6):249-60. PubMed ID: 8013268
    [Abstract] [Full Text] [Related]

  • 9. Increased glomerular thromboxane synthesis as a possible cause of proteinuria in experimental nephrosis.
    Remuzzi G, Imberti L, Rossini M, Morelli C, Carminati C, Cattaneo GM, Bertani T.
    J Clin Invest; 1985 Jan; 75(1):94-101. PubMed ID: 4038407
    [Abstract] [Full Text] [Related]

  • 10. Mycophenolate mofetil combined with a cyclooxygenase-2 inhibitor ameliorates murine lupus nephritis.
    Zoja C, Benigni A, Noris M, Corna D, Casiraghi F, Pagnoncelli M, Rottoli D, Abbate M, Remuzzi G.
    Kidney Int; 2001 Aug; 60(2):653-63. PubMed ID: 11473648
    [Abstract] [Full Text] [Related]

  • 11. Physiologic role for enhanced renal thromboxane production in murine lupus nephritis.
    Spurney RF, Bernstein RJ, Ruiz P, Pisetsky DS, Coffman TM.
    Prostaglandins; 1991 Jul; 42(1):15-28. PubMed ID: 1771236
    [Abstract] [Full Text] [Related]

  • 12. Effects of KW-3635, a specific thromboxane A2-receptor antagonist, on the development of lupus nephritis in NZB x NZW F1 mice.
    Kawakage M, Mizumoto H, Nukui E, Sato S, Karasawa A.
    Jpn J Pharmacol; 1993 Dec; 63(4):433-8. PubMed ID: 8121078
    [Abstract] [Full Text] [Related]

  • 13. The effects of a thromboxane synthase inhibitor, a prostacyclin analog and PGE1 on the nephritis of the NZB/W F1 mouse.
    Clark WF, Parbtani A, McDonald JW, Taylor N, Reid BD, Kreeft J.
    Clin Nephrol; 1987 Dec; 28(6):288-94. PubMed ID: 2450713
    [Abstract] [Full Text] [Related]

  • 14. Thromboxane receptor blockade reduces renal injury in murine lupus nephritis.
    Spurney RF, Fan PY, Ruiz P, Sanfilippo F, Pisetsky DS, Coffman TM.
    Kidney Int; 1992 Apr; 41(4):973-82. PubMed ID: 1387435
    [Abstract] [Full Text] [Related]

  • 15. Selective cyclooxygenase-2 inhibitor suppresses renal thromboxane production but not proliferative lesions in the MRL/lpr murine model of lupus nephritis.
    Oates JC, Halushka PV, Hutchison FN, Ruiz P, Gilkeson GS.
    Am J Med Sci; 2011 Feb; 341(2):101-5. PubMed ID: 20924284
    [Abstract] [Full Text] [Related]

  • 16. Effects of dazmegrel, piroxicam and cyclophosphamide on the NZB/W model of SLE.
    Archer RL, Cunningham AC, Moore PF, Potter JA, Bliven ML, Otterness IG.
    Agents Actions; 1989 Jun; 27(3-4):369-74. PubMed ID: 2801326
    [Abstract] [Full Text] [Related]

  • 17. Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide.
    Daikh DI, Wofsy D.
    J Immunol; 2001 Mar 01; 166(5):2913-6. PubMed ID: 11207238
    [Abstract] [Full Text] [Related]

  • 18. Reversal of established lupus nephritis and prolonged survival of New Zealand black x New Zealand white mice treated with the topoisomerase I inhibitor irinotecan.
    Frese-Schaper M, Zbaeren J, Gugger M, Monestier M, Frese S.
    J Immunol; 2010 Feb 15; 184(4):2175-82. PubMed ID: 20083657
    [Abstract] [Full Text] [Related]

  • 19. Enhanced glomerular thromboxane A2 mediates some pathophysiologic effect of platelet-activating factor in rabbit nephrotoxic nephritis: evidence from biochemical measurements and inhibitor trials.
    Macconi D, Benigni A, Morigi M, Ubiali A, Orisio S, Livio M, Perico N, Bertani T, Remuzzi G, Patrono C.
    J Lab Clin Med; 1989 May 15; 113(5):549-60. PubMed ID: 2541212
    [Abstract] [Full Text] [Related]

  • 20. Glomerular prostaglandin and thromboxane synthesis in rat nephrotoxic serum nephritis. Effects on renal hemodynamics.
    Lianos EA, Andres GA, Dunn MJ.
    J Clin Invest; 1983 Oct 15; 72(4):1439-48. PubMed ID: 6685136
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.